Lenire, the treatment device shown to reduce tinnitus symptoms in 95% of patients, is now available in Denmark
Neuromod Devices has reached an agreement with Specialklinikken Borgå ApS, Denmark’s longest established provider of private care for tinnitus, to make its Lenire device available in Denmark. Through this distribution agreement, Specialklinikken Borgå’s specialist team has exclusive licence from Neuromod to provide Lenire, throughout Denmark, to suitable patients for the treatment of their tinnitus.
“I’m proud that by working with Specialklinikken Borgå we can make Lenire available to people living with tinnitus in Denmark. Tinnitus is globally recognised as a significant healthcare challenge and many people living with the condition have unmet clinical needs. By partnering with tinnitus specialists like Specialklinikken Borgå we’re aiming to improve therapeutic outcomes for these people,” explains Dr Ross O’Neill, Founder and CEO of Neuromod Devices.
The agreement comes following Lenire’s launches in Norway and Spain earlier in 2022 and the publication of an independent real-world study demonstrating the safety and efficacy of the Lenire device for improving symptoms in tinnitus patients. The study found that 85% of tinnitus patients experienced a reduction in their tinnitus symptoms, as measured by THI1, following six to 12 weeks of treatment using Lenire2. The results were recently published in the highly ranked scientific journal, Brain Stimulation.
The device has also been used in large-scale clinical trials with over 500 patients. The second of these clinical trials was recently published in Nature – Scientific Reports. The results of this trial showed greater average improvement in tinnitus symptoms than the first trial due to optimised treatment plans for participants3. 95% of treatment-compliant participants reported an improvement in their tinnitus symptoms3.
Tinnitus Seminars Roadshow
To coincide with the introduction of Lenire to the Danish market, Specialklinikken Borgå ApS is hosting a roadshow of tinnitus seminars throughout Denmark for people living with tinnitus. The roadshow begins in Aarhus with further events in Middlefart, Skive, Odense, Copenhagen, Aalborg, and Esbjerg throughout July and August. Further details about each seminar and tickets are available at https://borgaa.com/.
“I’m delighted that Specialklinikken Borgå are partnering with Neuromod so we can provide an evidence-based treatment option that has seen encouraging patient outcomes in large-scale clinical trials and in the real world. I’m especially looking forward to our roadshow of tinnitus seminars to provide people with tinnitus an opportunity to discuss the breakthrough Lenire treatment,” explains Thomas Borgå, CEO at Specialklinikken Borgå.
Lenire is a bimodal neuromodulation device which combines mild electrical pulses to the tongue with sound stimulation to drive neuroplasticity in the brain which reduces the symptoms of tinnitus. It has CE-mark certification for the treatment of tinnitus under the supervision of an appropriately qualified healthcare professional and is currently available throughout Europe.
Denmark is the latest country that Lenire is available in following significant expansion of the device’s availability throughout Europe, including the UK, Spain, Switzerland, and Austria. Find out where Lenire is available using our clinical map.
References
1 THI or Tinnitus Handicap Inventory is a clinical standard for measuring the impact of tinnitus on someone’s day-to-day life. Measured on a scale of 100, the higher the score, the greater the impact of tinnitus. Reducing a person’s THI score should correspond to improved quality of life by reducing how their tinnitus is affecting them.
2 Buechner A, Lesinski-Schiedat A, Becker P, Lenarz T, Real-world clinical experience with bimodal neuromodulation for the treatment of tinnitus – A case series, Brain Stimulation (2022), doi: https://doi.org/10.1016/j.brs.2022.01.022.
3 Conlon et al., Different bimodal neuromodulation settings reduce tinnitus symptoms in a large randomized trial, Sci Rep, https://doi.org/10.1038/s41598-022-13875-x (2022)
